{"entity":{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","aka":[],"tldr":"A lung cancer oncologist who has helped test checkpoint inhibitors and next-generation ADCs in Korean patients.","summary":"Se-Hoon Lee is Professor of Internal Medicine at Seoul National University Hospital, working in thoracic oncology and immunotherapy. He has helped test checkpoint inhibitors and next-generation antibody-drug conjugates in Korean patients, including the datopotamab deruxtecan and tarlatamab programmes in non-small-cell and small-cell lung cancer. His publications include a phase 2 trial of vandetanib in pretreated lung cancer harbouring RET rearrangements and a study of the clonal history and genetic predictors of transformation from lung adenocarcinoma into small-cell carcinoma. His interests are lung cancer, immunotherapy and small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SH%5BAuthor%5D%20Seoul%20National%20University%20lung%20immunotherapy"}],"tags":[],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["datopotamab-deruxtecan","tarlatamab"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; thoracic oncology and immunotherapy","institutionId":"snuh","specialisms":["Lung cancer","Immunotherapy","Small-cell lung cancer"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SH%5BAuthor%5D%20Seoul%20National%20University%20lung%20immunotherapy"}],"papers":[{"title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","journal":"Annals of Oncology","year":2017,"doi":"10.1093/annonc/mdw559"},{"title":"Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.71.9096"},{"title":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2403614","doi":"10.1056/NEJMoa2403614"}]},"route":"/people/lee-se-hoon/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"institution":[{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/"}],"paper":[{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/"}]}}